Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
Department of Pharmacology, Al-Azhar University, Assiut 71524, Egypt.
World J Gastroenterol. 2023 Jan 21;29(3):425-449. doi: 10.3748/wjg.v29.i3.425.
The coronavirus disease 2019 (COVID-19) represents a global health and economic challenge. Hepatic injuries have been approved to be associated with severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection. The viral tropism pattern of SARS-CoV-2 can induce hepatic injuries either by itself or by worsening the conditions of patients with hepatic diseases. Besides, other factors have been reported to play a crucial role in the pathological forms of hepatic injuries induced by SARS-CoV-2, including cytokine storm, hypoxia, endothelial cells, and even some treatments for COVID-19. On the other hand, several groups of people could be at risk of hepatic COVID-19 complications, such as pregnant women and neonates. The present review outlines and discusses the interplay between SARS-CoV-2 infection and hepatic injury, hepatic illness comorbidity, and risk factors. Besides, it is focused on the vaccination process and the role of developed vaccines in preventing hepatic injuries due to SARS-CoV-2 infection.
2019 年冠状病毒病(COVID-19)是一项全球性的健康和经济挑战。已证实肝损伤与严重急性呼吸综合征冠状病毒(SARS-CoV-2)感染有关。SARS-CoV-2 的病毒嗜性模式可通过自身或通过加重肝病患者的病情而导致肝损伤。此外,据报道,其他因素在 SARS-CoV-2 引起的肝损伤的病理形式中起着至关重要的作用,包括细胞因子风暴、缺氧、内皮细胞,甚至一些 COVID-19 的治疗方法。另一方面,有几类人群可能面临 COVID-19 相关肝并发症的风险,如孕妇和新生儿。本综述概述并讨论了 SARS-CoV-2 感染与肝损伤、肝疾病合并症和危险因素之间的相互作用。此外,它还侧重于疫苗接种过程以及已开发疫苗在预防 SARS-CoV-2 感染引起的肝损伤中的作用。